Kythera Biopharmaceuticals Company Profile (NASDAQ:KYTH)

About Kythera Biopharmaceuticals

Kythera Biopharmaceuticals logoKYTHERA Biopharmaceuticals, Inc. (KYTHERA) is a clinical-stage biopharmaceutical company engaged in the discovery, development and commercialization of prescription products for the aesthetic medicine market. The Company's initial focus is on the facial aesthetics market. The Company's product candidate is ATX101, an injectable drug in late-stage clinical development for the treatment of submental fullness associated with submental fat, which commonly presents as an undesirable double chin. ATX101 is a formulation of a purified synthetic version of deoxycholic acid. The Company has completed Phase III clinical trials for ATX101 and has made regulatory filings outside the United States, in Canada, Switzerland and Australia.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Drug Manufacturers - Major
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: KYTH
  • CUSIP: 50157010
Key Metrics:
  • Previous Close: $74.98
  • 50 Day Moving Average: $74.78
  • 200 Day Moving Average: $62.97
  • 52-Week Range: $29.86 - $76.31
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -22.72
  • P/E Growth: 0.00
  • Market Cap: $N/A
Additional Links:
Companies Related to Kythera Biopharmaceuticals:

Analyst Ratings

Consensus Ratings for Kythera Biopharmaceuticals (NASDAQ:KYTH) (?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for Kythera Biopharmaceuticals (NASDAQ:KYTH)
Show:
DateFirmActionRatingPrice TargetDetails
6/29/2015Leerink SwannDowngradeOutperform -> Market Perform$61.00 -> $75.00View Rating Details
6/8/2015GuggenheimInitiated CoverageBuy$64.00View Rating Details
4/10/2015Bank of America CorpInitiated CoverageBuy$66.00 -> $47.00View Rating Details
(Data available from 2/24/2015 forward)

Earnings

Earnings History for Kythera Biopharmaceuticals (NASDAQ:KYTH)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/9/2015        
8/5/2015Q2($1.15)($1.44)ViewN/AView Earnings Details
5/7/2015Q115($1.12)$1.24ViewN/AView Earnings Details
3/2/2015Q414($1.07)($1.07)ViewN/AView Earnings Details
8/7/2014Q2($0.83)($0.86)ViewListenView Earnings Details
5/8/2014Q1($0.67)($3.18)ViewListenView Earnings Details
3/17/2014Q413($0.69)($0.66)ViewN/AView Earnings Details
11/14/2013Q313($0.72)($0.62)ViewN/AView Earnings Details
8/6/2013Q2 2013($0.70)($0.67)ViewN/AView Earnings Details
5/13/2013Q1 2013($0.97)($0.77)ViewN/AView Earnings Details
3/21/2013Q4 2012($0.76)($1.04)ViewN/AView Earnings Details
11/13/2012Q312($11.41)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Kythera Biopharmaceuticals (NASDAQ:KYTH)
Current Year EPS Consensus Estimate: $-4.45 EPS
Next Year EPS Consensus Estimate: $-3.30 EPS

Dividends

Dividend History for Kythera Biopharmaceuticals (NASDAQ:KYTH)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Kythera Biopharmaceuticals (NASDAQ:KYTH)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/24/2015Frederick Beddingfield IIIinsiderSell110,638$74.91$8,287,892.58View SEC Filing  
9/24/2015John W. SmitherCFOSell53,835$74.90$4,032,241.50View SEC Filing  
9/23/2015Elisabeth SandovalinsiderSell83,122$74.90$6,225,837.80View SEC Filing  
9/23/2015Keith KleinGeneral CounselSell52,153$74.90$3,906,259.70View SEC Filing  
9/22/2015John W. SmitherCFOSell6,645$74.91$497,776.95View SEC Filing  
9/22/2015Keith KleinGeneral CounselSell10,589$74.90$793,116.10View SEC Filing  
9/18/2015John W. SmitherCFOSell1,054$74.95$78,997.30View SEC Filing  
9/1/2015Camille D SamuelsDirectorSell250$74.72$18,680.00View SEC Filing  
6/25/2015Frederick Beddingfield IIIInsiderSell30,583$75.66$2,313,909.78View SEC Filing  
6/25/2015John W SmitherCFOSell4,600$75.50$347,300.00View SEC Filing  
5/1/2015Keith R LeonardCEOSell13,000$44.93$584,090.00View SEC Filing  
4/30/2015Elisabeth SandovalInsiderSell1,654$45.55$75,339.70View SEC Filing  
4/30/2015John W SmitherCFOSell2,041$45.49$92,845.09View SEC Filing  
4/30/2015Keith R LeonardCEOSell5,557$45.29$251,676.53View SEC Filing  
4/15/2015Keith R LeonardCEOSell2,709$50.52$136,858.68View SEC Filing  
4/1/2015Keith R LeonardCEOSell13,548$48.14$652,200.72View SEC Filing  
3/16/2015Keith R LeonardCEOSell5,312$50.16$266,449.92View SEC Filing  
3/9/2015Nathaniel E DavidDirectorSell6,185$55.00$340,175.00View SEC Filing  
3/5/2015John W SmitherCFOSell4,200$48.09$201,978.00View SEC Filing  
3/5/2015Nathaniel E DavidDirectorSell12,375$48.49$600,063.75View SEC Filing  
3/2/2015Keith R LeonardCEOSell10,625$40.94$434,987.50View SEC Filing  
3/2/2015Nathaniel E DavidDirectorSell1,875$40.78$76,462.50View SEC Filing  
2/18/2015John W SmitherCFOSell2,000$41.00$82,000.00View SEC Filing  
2/17/2015Keith R LeonardCEOSell4,165$40.46$168,515.90View SEC Filing  
2/2/2015Keith R LeonardCEOSell6,249$36.70$229,338.30View SEC Filing  
2/2/2015Nathaniel E DavidDirectorSell1,715$36.76$63,043.40View SEC Filing  
1/29/2015John W SmitherCFOSell1,000$38.00$38,000.00View SEC Filing  
1/23/2015John W SmitherCFOSell3,000$35.65$106,950.00View SEC Filing  
1/16/2015Camille D SamuelsDirectorSell250$36.70$9,175.00View SEC Filing  
1/2/2015Keith R LeonardCEOSell6,120$35.37$216,464.40View SEC Filing  
1/2/2015Nathaniel E DavidDirectorSell1,680$35.30$59,304.00View SEC Filing  
12/1/2014Keith R LeonardCEOSell5,994$37.60$225,374.40View SEC Filing  
12/1/2014Nathaniel E DavidDirectorSell1,645$37.67$61,967.15View SEC Filing  
11/3/2014Keith R LeonardCEOSell5,865$34.95$204,981.75View SEC Filing  
11/3/2014Nathaniel E DavidDirectorSell1,610$34.90$56,189.00View SEC Filing  
10/23/2014Keith R LeonardCEOSell1,913$35.13$67,203.69View SEC Filing  
10/1/2014Keith R LeonardCEOSell3,826$32.55$124,536.30View SEC Filing  
10/1/2014Nathaniel E DavidDirectorSell1,350$32.60$44,010.00View SEC Filing  
9/2/2014Nathaniel E DavidDirectorSell1,540$37.37$57,549.80View SEC Filing  
8/4/2014Keith R LeonardCEOSell1,828$35.10$64,162.80View SEC Filing  
8/4/2014Nathaniel E DavidDirectorSell1,505$33.08$49,785.40View SEC Filing  
8/1/2014Keith R LeonardCEOSell3,656$32.80$119,916.80View SEC Filing  
7/2/2014John W SmitherCFOSell2,250$40.00$90,000.00View SEC Filing  
7/2/2014Keith R LeonardCEOSell8,925$39.47$352,269.75View SEC Filing  
7/2/2014Nathaniel E DavidDirectorSell1,778$39.20$69,697.60View SEC Filing  
6/16/2014Keith R LeonardCEOSell1,743$36.58$63,758.94View SEC Filing  
6/2/2014Keith R LeonardCEOSell3,486$32.54$113,434.44View SEC Filing  
6/2/2014Nathaniel E DavidDirectorSell1,230$32.56$40,048.80View SEC Filing  
5/1/2014Keith LeonardCEOSell3,400$32.56$110,704.00View SEC Filing  
5/1/2014Nathaniel DavidDirectorSell1,200$32.60$39,120.00View SEC Filing  
4/1/2014Jeffrey WebsterVPSell4,000$39.36$157,440.00View SEC Filing  
4/1/2014Keith LeonardCEOSell13,260$39.08$518,200.80View SEC Filing  
3/20/2014John SmitherCFOSell1,125$43.78$49,252.50View SEC Filing  
3/3/2014Jeffrey WebsterVPSell4,000$49.55$198,200.00View SEC Filing  
3/3/2014Nathaniel DavidDirectorSell5,099$49.18$250,768.82View SEC Filing  
2/20/2014John SmitherCFOSell2,250$49.75$111,937.50View SEC Filing  
2/14/2014John SmitherCFOSell1,125$50.00$56,250.00View SEC Filing  
2/3/2014Jeffrey WebsterVPSell4,000$45.40$181,600.00View SEC Filing  
2/3/2014Keith LeonardCEOSell12,740$45.35$577,759.00View SEC Filing  
2/3/2014Nathaniel DavidDirectorSell5,000$45.31$226,550.00View SEC Filing  
1/21/2014John SmitherCFOSell1,125$42.54$47,857.50View SEC Filing  
1/2/2014Jeffrey WebsterVPSell4,000$37.38$149,520.00View SEC Filing  
1/2/2014Keith LeonardCEOSell12,480$37.38$466,502.40View SEC Filing  
12/2/2013Jeffrey WebsterVPSell4,000$38.69$154,760.00View SEC Filing  
12/2/2013Keith LeonardCEOSell12,220$38.95$475,969.00View SEC Filing  
12/2/2013Nathaniel DavidDirectorSell4,800$38.72$185,856.00View SEC Filing  
11/1/2013Jeffrey D WebsterVPSell4,000$44.90$179,600.00View SEC Filing  
11/1/2013Keith R LeonardCEOSell11,960$44.22$528,871.20View SEC Filing  
11/1/2013Nathaniel E DavidDirectorSell4,698$43.93$206,383.14View SEC Filing  
9/16/2013Keith LeonardCEOSell2,860$33.62$96,153.20View SEC Filing  
9/10/2013John W SmitherCFOSell40,000$30.02$1,200,800.00View SEC Filing  
9/10/2013Keith KleinGeneral CounselSell4,500$32.00$144,000.00View SEC Filing  
9/10/2013Nathaniel E DavidDirectorSell6,376$31.00$197,656.00View SEC Filing  
9/3/2013Jeffrey WebsterVPSell4,000$26.11$104,440.00View SEC Filing  
9/3/2013Keith LeonardCEOSell8,580$26.12$224,109.60View SEC Filing  
9/3/2013Nathaniel DavidDirectorSell3,375$26.12$88,155.00View SEC Filing  
8/1/2013Jeffrey D WebsterVPSell4,000$26.76$107,040.00View SEC Filing  
8/1/2013John W SmitherCFOSell10,000$26.80$268,000.00View SEC Filing  
8/1/2013Keith R LeonardCEOSell8,385$26.73$224,131.05View SEC Filing  
8/1/2013Nathaniel E DavidDirectorSell3,301$26.76$88,334.76View SEC Filing  
7/15/2013Keith R LeonardCEOSell1,365$28.90$39,448.50View SEC Filing  
7/1/2013Jeffrey D WebsterVPSell4,000$27.06$108,240.00View SEC Filing  
7/1/2013Keith R LeonardCEOSell8,190$27.10$221,949.00View SEC Filing  
7/1/2013Nathaniel E DavidDirectorSell3,225$27.07$87,300.75View SEC Filing  
6/28/2013Keith KleinGeneral CounselSell4,500$27.00$121,500.00View SEC Filing  
6/17/2013John W SmitherCFOSell6,000$26.00$156,000.00View SEC Filing  
6/17/2013Keith R LeonardCEOSell1,332$25.69$34,219.08View SEC Filing  
6/17/2013Nathaniel E DavidDirectorSell1,538$26.00$39,988.00View SEC Filing  
6/7/2013Jeffrey D WebsterVPSell4,000$25.00$100,000.00View SEC Filing  
6/3/2013Keith R LeonardCEOSell6,663$21.25$141,588.75View SEC Filing  
5/31/2013Jeffrey D WebsterVPSell4,000$22.26$89,040.00View SEC Filing  
5/1/2013Nathaniel E DavidDirectorSell2,625$21.42$56,227.50View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Kythera Biopharmaceuticals (NASDAQ:KYTH)
DateHeadline
News IconExecutive-Level Specialty Medical and Biopharmaceutical Sales Management Professional Joins Cohera Medical, Inc.® - P&T Community (NASDAQ:KYTH)
www.ptcommunity.com - February 23 at 5:22 AM
News IconExecutive-Level Specialty Medical And Biopharmaceutical Sales Management Professional Joins Cohera Medical (NASDAQ:KYTH)
www.biospace.com - February 22 at 6:24 PM
News IconExecutive-Level Specialty Medical and Biopharmaceutical Sales Management Professional Joins Cohera Medical, Inc.® (NASDAQ:KYTH)
www.pharmiweb.com - February 22 at 12:22 PM
News IconKythera Biopharmaceuticals, Inc. (NASDAQ:KYTH) Valuation According To Analysts - UK Market News (NASDAQ:KYTH)
www.ukmarketnews.co.uk - February 17 at 9:27 AM
News IconAllergan continues to shapes product portfolio with $2.48B acquisition of Zeltiq (NASDAQ:KYTH)
medicaldevicedaily.com - February 14 at 12:19 AM
News IconNorthern Europe: market of fish or marine mammals fats - Satellite PR News (press release) (NASDAQ:KYTH)
www.satprnews.com - February 11 at 5:02 AM
News IconCubic Pharmaceuticals Has Successful ECRM Trade Show (NASDAQ:KYTH)
www.bio-medicine.org - February 8 at 6:59 PM
News IconKythera Biopharmaceuticals, Inc. (NASDAQ:KYTH) Updated Broker Ratings - NewsDen (NASDAQ:KYTH)
newsden.net - February 2 at 12:03 AM
News IconBrokers Release Average Price Target Of 63.50 On Kythera Biopharmaceuticals, Inc. (NASDAQ:KYTH) - UK Market News (NASDAQ:KYTH)
www.ukmarketnews.co.uk - January 25 at 7:37 PM
News IconKythera Biopharmaceuticals Inc KYTH Pharmaceuticals Healthcare Deals and Alliances Profile Prices from USD $250 (NASDAQ:KYTH)
www.bioportfolio.com - January 18 at 6:44 PM
seekingalpha.com logoNeothetics: A Look Ahead - Seeking Alpha (NASDAQ:KYTH)
seekingalpha.com - December 22 at 12:47 AM
seekingalpha.com logoNeothetics: A Look Ahead (NASDAQ:KYTH)
seekingalpha.com - December 21 at 7:03 PM
globenewswire.com logoNohla Therapeutics Announces Closing of $43.5M Series A Financing to Transform Stem Cell Transplantation with ... - GlobeNewswire (press release) (NASDAQ:KYTH)
globenewswire.com - November 30 at 6:21 PM
finance.yahoo.com logoNohla Therapeutics Announces Closing of $43.5M Series A Financing to Transform Stem Cell Transplantation … (NASDAQ:KYTH)
finance.yahoo.com - November 29 at 4:15 PM
finance.yahoo.com logoNohla Therapeutics Announces Closing of $43.5M Series A Financing to Transform Stem Cell Transplantation … (NASDAQ:KYTH)
finance.yahoo.com - November 29 at 4:15 PM
einnews.com logoNohla Therapeutics Announces Closing of $43.5M Series A Financing to Transform Stem Cell Transplantation with Innovative ... (NASDAQ:KYTH)
semiconductors.einnews.com - November 29 at 4:15 PM
einnews.com logoNohla Therapeutics Announces Closing of $43.5M Series A Financing to Transform Stem Cell Transplantation with Innovative ... (NASDAQ:KYTH)
semiconductors.einnews.com - November 29 at 4:15 PM
News IconKythera Biopharmaceuticals, Inc. KYTH Pharmaceuticals Healthcare Deals and Alliances Profile Prices from USD $250 (NASDAQ:KYTH)
www.bioportfolio.com - November 23 at 5:57 PM
News IconThere's now an injection to get rid of your double chin - Honey Fashion and Beauty (NASDAQ:KYTH)
style.nine.com.au - November 23 at 8:51 AM
News IconThere's now an injection to get rid of your double chin And it's going to be available in Australia very soon - Honey Fashion and Beauty (NASDAQ:KYTH)
style.nine.com.au - November 22 at 9:55 AM
investopedia.com logo6 Reasons to Watch Kythera Biopharm Inc. (AGN, PFE) (NASDAQ:KYTH)
www.investopedia.com - November 19 at 8:28 AM
News IconVetStem Biopharma Begins Enrollment in Pivotal FDA Clinical Study of Osteoarthritis in Dogs (NASDAQ:KYTH)
www.bio-medicine.org - November 17 at 5:30 PM
News IconConejo Biotech Vet Joins Startup (NASDAQ:KYTH)
sfvbj.com - November 3 at 5:52 PM
News IconConejo Biotech Vet Joins Startup - San Fernando Valley Business Journal (NASDAQ:KYTH)
www.sfvbj.com - November 3 at 9:37 AM
News IconAnti-Aging Startup Raises $116 Million With big VCs and Amazon CEO Jeff Bezos Backing - Next Big Future (NASDAQ:KYTH)
www.nextbigfuture.com - October 28 at 5:43 PM
seekingalpha.com logoAlder BioPharmaceuticals' (ALDR) CEO Randy Schatzman on Q3 ... - Seeking Alpha (NASDAQ:KYTH)
seekingalpha.com - October 28 at 9:25 AM
News IconMy oh Myovant! $217M IPO, phase IIIs near; Unity joins finance party with $116M series B - BioWorld Online (NASDAQ:KYTH)
www.bioworld.com - October 28 at 9:25 AM
bloomberg.com logoAnti-Aging Startup Raises $116 Million With Bezos Backing - Bloomberg (NASDAQ:KYTH)
www.bloomberg.com - October 28 at 9:25 AM
News IconUNITY Biotechnology Announces $116 Million Series B Financing - KAIT Jonesboro, AR - Region 8 News, weather, sports (NASDAQ:KYTH)
www.kait8.com - October 27 at 5:55 PM
finance.yahoo.com logoUNITY Biotechnology Announces $116 Million Series B Financing (NASDAQ:KYTH)
finance.yahoo.com - October 27 at 5:55 PM
bloomberg.com logoAnti-Aging Startup Raises $116 Million With Bezos Backing (1) (NASDAQ:KYTH)
washpost.bloomberg.com - October 27 at 5:55 PM
News IconAnti-aging startup backed by Fidelity, Bezos raises $116 million (NASDAQ:KYTH)
www.pressherald.com - October 27 at 5:55 PM
News IconSodium Deoxycholate for Submental Contouring (NASDAQ:KYTH)
www.medscape.com - October 22 at 5:33 PM
News IconBlackThorn Therapeutics Launches to Develop Novel, Targeted Treatments for Neurobehavioral Disorders (NASDAQ:KYTH)
www.cbs58.com - October 20 at 6:11 PM
businesswire.com logoBlackThorn Therapeutics Launches to Develop Novel, Targeted Treatments for Neurobehavioral Disorders - Business Wire (press release) (NASDAQ:KYTH)
www.businesswire.com - October 20 at 11:34 AM
prnewswire.com logoPfenex Inc. Announces Formation of Scientific Advisory Board - PR Newswire (press release) (NASDAQ:KYTH)
www.prnewswire.com - October 20 at 11:34 AM
finance.yahoo.com logoPfenex Inc. Announces Formation of Scientific Advisory Board (NASDAQ:KYTH)
finance.yahoo.com - October 19 at 6:13 PM
News Icon$67 Million Thousand Oaks Multifamily Sale Closed by Marcus & Millichap’s IPA Division (NASDAQ:KYTH)
ih.advfn.com - October 5 at 11:08 AM
News IconKythera Biopharmaceuticals, Inc. (NASDAQ:KYTH) Latest Broker Views - NewsDen (NASDAQ:KYTH)
newsden.net - October 1 at 11:14 AM
News IconKythera Biopharmaceuticals, Inc. (NASDAQ:KYTH) Latest Broker Coverage - NewsDen (NASDAQ:KYTH)
newsden.net - September 29 at 5:50 PM
News IconIMT Westlake Village Apartment Complex in Los Angeles Sells for $88.2M - REBusinessOnline (NASDAQ:KYTH)
rebusinessonline.com - September 1 at 8:56 AM
News IconIMT Westlake Village Apartment Complex in Los Angeles Sells for $88.2M (NASDAQ:KYTH)
rebusinessonline.com - August 31 at 10:43 AM
News Icon$88.25 Million Ventura County Multifamily Sale Closed by Marcus & Millichaps IPA Division (NASDAQ:KYTH)
www.cbs58.com - August 30 at 5:55 PM
News IconMedical Aesthetics Market Worth $69786 Million by 2021 - MENAFN.COM (NASDAQ:KYTH)
www.menafn.com - August 11 at 6:09 PM
bizjournals.com logoMedical Aesthetics Market Worth $69,786 Million by 2021 (NASDAQ:KYTH)
www.bizjournals.com - August 10 at 8:52 AM
News IconTeva/Actavis merger's FTC scrutiny creates another pharma winner - BioWorld Online (NASDAQ:KYTH)
www.bioworld.com - August 4 at 6:14 PM
streetinsider.com logoMannKind (MNKD) Assumes Responsibility for Distribution of Afrezza; Launches Patient Reimbursement Programs - StreetInsider.com (NASDAQ:KYTH)
www.streetinsider.com - August 1 at 5:45 PM
finance.yahoo.com logoMannkind Assumes Responsibility for Distribution of Afrezza® and Launches Patient Reimbursement and Adherence Support Programs (NASDAQ:KYTH)
finance.yahoo.com - August 1 at 10:38 AM
businesswire.com logoSienna Biopharmaceuticals Announces Second Closing of Series A Financing - Business Wire (press release) (NASDAQ:KYTH)
www.businesswire.com - July 13 at 6:17 PM
tmcnet.com logoSienna Biopharmaceuticals Announces Second Closing of Series A Financing (NASDAQ:KYTH)
www.tmcnet.com - July 13 at 8:52 AM

Social

What is Kythera Biopharmaceuticals' stock symbol?

Kythera Biopharmaceuticals trades on the NASDAQ under the ticker symbol "KYTH."

When will Kythera Biopharmaceuticals announce their earnings?

Kythera Biopharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, November, 9th 2015.

How do I buy Kythera Biopharmaceuticals stock?

Shares of Kythera Biopharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Kythera Biopharmaceuticals stock cost?

One share of Kythera Biopharmaceuticals stock can currently be purchased for approximately $74.98.

Kythera Biopharmaceuticals (NASDAQ:KYTH) Chart for Friday, February, 24, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for Kythera Biopharmaceuticals (NASDAQ:KYTH)

Earnings History Chart

Earnings by Quarter for Kythera Biopharmaceuticals (NASDAQ:KYTH)

Dividend History Chart

Dividend Payments by Quarter for Kythera Biopharmaceuticals (NASDAQ:KYTH)

Last Updated on 2/24/2017 by MarketBeat.com Staff